Skip to main content
OpenTrials

Clinical trial condition

Carcinosarcoma

Explore clinical trials studying Carcinosarcoma. Study availability and eligibility vary by location and protocol.

25 public trials 7 recruiting studies
Refine in advanced search Browse all conditions

Carcinosarcoma trial results

Completed

ZW25 in Women With Endometrial Cancers

NCT04513665

Conditions
Carcinosarcoma, Endometrial Cancer, Endometrial Neoplasms, +15 more
Locations
  • Memorial Sloan Kettering Basking Ridge (Limited protocol activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited protocol activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited protocol activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities) Commack, New York, United States
View Trial Details
Completed

A Study of Nivolumab in Selected Uterine Cancer Patients

NCT03241745

Conditions
Adenocarcinoma, Adenocarcinoma, Clear Cell, Carcinoma, +25 more
Locations
  • Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
  • Memorial Sloan Kettering Commack Commack, New York, United States
View Trial Details
Completed

Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors

NCT00815945

Conditions
Carcinosarcoma, Leiomyosarcoma, Mesenchymal Tumor, +6 more
Locations
  • Charité, Campus Virchow Klinikum, Frauenklinik Berlin, Germany
  • Malteser Krankenhaus, Gynäkologie und Geburtshilfe Bonn, Germany
  • Klinikum Bremen-Mitte gGmbH, Frauenklinik Bremen, Germany
  • Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe Dresden, Germany
View all 15 locations
View Trial Details
Active, Not Recruiting

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

NCT03914612

Conditions
Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, +30 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro Jonesboro, Arkansas, United States
View all 397 locations
View Trial Details
Active, Not Recruiting

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

NCT04214067

Conditions
Carcinosarcoma, Endometrial Endometrioid Adenocarcinoma, Neoplasms, +6 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Community Cancer Institute Clovis, California, United States
  • University Oncology Associates Clovis, California, United States
  • John Muir Medical Center-Concord Concord, California, United States
View all 280 locations
View Trial Details
Active, Not Recruiting

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

NCT03660826

Conditions
Adenocarcinoma, Adnexal Diseases, Carcinoma, +28 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 762 locations
View Trial Details
Active, Not Recruiting

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Conditions
Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, +80 more
Locations
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
View all 23 locations
View Trial Details

Related conditions